BMS-929075

BMS‑929075 is a potent, orally bioavailable small molecule developed by Bristol Myers Squibb as an allosteric inhibitor of the hepatitis C virus (HCV) NS5B RNA-dependent RNA polymerase. It specifically targets the palm site of the NS5B replicase, interfering with viral replication. The compound demonstrated high oral bioavailability and promising pharmacokinetic properties in preclinical studies and phase I clinical trials. Its primary indication was for the treatment of chronic HCV infection; however, clinical development did not progress beyond early-phase trials[1][2][4][5].

Other names

4-fluoro-2-(4-fluorophenyl)-N-methyl-5-(2-methyl-5-{[1-(pyrimidin-2-yl)cyclopropyl]carbamoyl}phenyl)-1-benzofuran-3-carboxamide4-Fluoro-2-(4-fluorophenyl)-n-methyl-5-(2-methyl-5-\((1\)-(pyrimidin-2-yl)cyclopropyl)carbamoyl)phenyl)benzofuran-3-carboxamide